Lutz et al, Neuropsychopharmacology

Slides:

Advertisements

Similar presentations

Rate Rhythm P-R Interval QRS Duration P-QRS Ratio Treatment Causes.

Advertisements

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

P449. p450 Figure 15-1 p451 Figure 15-2 p453 Figure 15-2a p453.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Pregnancy and Drug Abuse Eva Janecek-Rucker. Learning Objectives 1.To develop a knowledge base of the effects of substances of abuse (e.g., alcohol, cocaine,

Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.

Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.

Statistics Horizon Behavioral Health

ABAE positive cells 6h after treatment

A B C D Rao et al., 2012; Supplementary Figure S1 p = 0.03 p = NS

Supplementary Figure 1 Shiota et al.

Daniel J. Lenihan et al. BTS 2016;1:

Checklist for Site Reconnaissance (Sabatini et al_2002)

Chapter 15 D.3: Opiates Potent medical drugs prepared by chemical modification of natural products can be addictive and become substances of abuse.

Nat. Rev. Neurol. doi: /nrneurol

A 4 Band intensity (relative unit) MMP-9 MMP-2 B C 4 4

Control SC236(5mM) SC236(5mM) SC236(25mM) SC236(25mM)

PGP9.5 ANTIGEN H & E A B Supplementary Figure 1, Ceyhan et al.

Median Tumor Development Time

Differences in awareness, treatment, and control of hypertension between Southerners and non-Southerners Hypertension awareness, treatment, and control.

Pain Management: Patients Maintained on Buprenorphine

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Sensible heat contribution to precipitation changes

Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo

Figure 2 The association between CD8+ T‑cell density of the tumour

Western blots Kleinjan et al., “Drug-tunable multi-dimensional Synthetic Gene Control using Inducible Degron-tagged dCas9 Effectors”. dCas9 dCas9 GFP Histone.

Volume 14, Issue 4, Pages (April 2015)

Nat. Rev. Endocrinol. doi: /nrendo

Treatment EPO (1 IU/ml) Placebo

Supplementary Table 1, Chauvier et al., 2011

Sequencing at 10,000x using Illumina paired reads

reproductive parts (g m-2 yr-1)

Nat. Rev. Endocrinol. doi: /nrendo

a c b d e * * －＋ Supplementary Figure 0.2 HCF (ALP / G3PDH) 0.1 SK-1

Supplementary Figure S5, Lecoeur et al.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Helena M. Viola et al. BTS 2018;3:

Impact of New Hepatitis C Treatments in Different Regions of the World

Supplementary Figure 2 Shiota et al.

Forest plot showing the number of adults (at the top) and children (lower down) who were admitted to hospital after treatment in the emergency department.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Between-night treatment effects of VR, petrolatum, and no treatment on (A) cough frequency (P = .003, 3-way treatment comparison), (B) cough severity (P.

HeLa COS-7 Supplementary Figure S1 Coelho et al (2014) MM pSPL3 MM

Kaplan-Meier survival curve demonstrating treatment duration of metformin and orlistat. Kaplan-Meier survival curve demonstrating treatment duration of.

Roth et al, Supplementary Figure 1

Bernard et al, Supplementary Figure S1

Supplementary Figure 1 ** ** _ _ + + a. b. ** ** _ _ + + c. n=3 RU486

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Nat. Rev. Cardiol. doi: /nrcardio

Supplementary Fig S1, Zembutsu H et al.

Leto et al., Supplementary Figure S3

Treatment with AZD5363 reduces the proportion of proliferating vascular endothelial cells and following RT, the influx of CD11b+ bone marrow‐derived cells.

Performance of chronic METH-treated rats in the gambling test under the double-reward condition. Performance of chronic METH-treated rats in the gambling.

Effects of tumour size on response to treatment in the KPC model.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

A B D C E F Supplementary Figure S4. Epping et al. IP: flag input IgG

Motivational effects of withdrawal in opiate-dependent animals after blocking BDNF function in the VTA. a, Knocking down TrkB in the VTA with LV-siRNAs.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

CAT displays very high in vivo stability as exemplified by a rat PK study. CAT displays very high in vivo stability as exemplified by a rat.

Kaplan-Meier plots of the duration of continuous albuterol, time until q4 albuterol, and hospital LOS for each of the 4 treatment groups. Kaplan-Meier.

CRA inhibits the growth of human tumor xenografts in vivo.

Distribution of SDS for serum creatinine, serum BUN, SBP, and DBP per quintiles of KS. Quintiles are expressed in SDS (see Figure 1B): 1st quintile,

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

**** *** * **** **** *** Shahriary et al.- Supplementary Figure 4 (a)

Presentation transcript:

Lutz et al, Neuropsychopharmacology Supplementary Figure 1. Lutz et al, Neuropsychopharmacology a Morphine (20-100 mg/kg) or Heroin (10-50 mg/kg) Opiate treatment Precipitated withdrawal b ¥ ¥ ¥ ¥

Lutz et al, Neuropsychopharmacology Supplementary Figure 2. Lutz et al, Neuropsychopharmacology a b +, # #

Lutz et al, Neuropsychopharmacology Supplementary Figure 3. Lutz et al, Neuropsychopharmacology a b n.d. n.d. c d * *

Supplementary Figure 4. Lutz et al, Neuropsychopharmacology * b ns * c ns * Heroin treatment Duration of abstinence